Reference
Pozo K, Zahler S, Ithimatsu K, Carter A, Telange R, Wang S, Pfragner R, Fujimoto J, Grubbs E, Takahashi M, et al. 2018. Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer, Oncotarget, 9: 37662-37675.